1 **SR-TWAS: Leveraging Multiple Reference Panels to Improve TWAS Power by Ensemble**
2 **Machine Learning**

3 Randy L. Parrish[1,2], Aron S. Buchman[3], Shinya Tasaki[3], Yanling Wang[3], Denis Avey[3], Jishu
4 Xu[3], Philip L. De Jager[4], David A. Bennett[3], Michael P. Epstein[1], Jingjing Yang[1*]
5
1. Center for Computational and Quantitative Genetics, Department of Human Genetics, Emory
University School of Medicine, Atlanta, GA, 30322, USA
2. Department of Biostatistics, Emory University School of Public Health, Atlanta, GA 30322,
USA
3. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, 60612, USA
4. Center for Translational and Computational Neuroimmunology, Department of Neurology
and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia
University Irving Medical Center, New York, NY10032, USA
14
[*] Correspondence Author: jingjing.yang@emory.edu

Abstract (150 words)

Multiple reference panels of a given tissue or multiple tissues often exist, and multiple regression

methods could be used for training gene expression imputation models for TWAS. To leverage

expression imputation models (i.e., base models) trained with multiple reference panels,

regression methods, and tissues, we develop a Stacked Regression based TWAS (SR-TWAS)

tool which can obtain optimal linear combinations of base models for a given validation

transcriptomic dataset. Both simulation and real studies showed that SR-TWAS improved power

due to increased effective training sample sizes and borrowed strength across multiple regression

methods and tissues. Leveraging base models across multiple reference panels, tissues, and

regression methods, our studies of Alzheimer's disease (AD) dementia and Parkinson's disease

(PD) identified respective 11 independent significant risk genes for AD (supplementary motor

area tissue) and 12 independent significant risk genes for PD (substantia nigra tissue), including

6 novels for AD and 6 novels for PD.

Introduction

Two-stage transcriptome-wide association study (TWAS) has been widely used in genetics

studies of complex traits, due to the convenience of using publicly available transcriptomic

reference panels and summary-level genome-wide association study (GWAS) datasets[1–5]. The

standard two-stage TWAS method[6,7] first trains gene expression imputation models (per gene per

tissue) using a transcriptomic reference panel (Stage I), taking quantitative gene expression traits

as response variables and nearby cis- or genome-wide (cis- and trans-) genetic variants as

predictors. The non-zero genetic effect sizes estimated in the gene expression imputation model

are considered effect sizes of a broad sense of expression quantitative trait loci (eQTL), which

are taken as variant weights to conduct gene-based association tests with GWAS data

(individual-level or summary-level) in Stage II.

Various TWAS techniques have been developed, employing diverse regression methods to train

models for imputing gene expression. Additionally, multiple transcriptomic reference panels are

made available to the public and could be used in TWAS. Consequently, it is possible to train

multiple gene expression imputation models by employing distinct regression methods,

employing multiple transcriptomic reference panels of the same tissue type, or utilizing

transcriptomic data from multiple tissues within a given reference panel. For example, multiple

regression methods, such as penalized regression with Elastic-Net penalty (used by PrediXcan[7])

and nonparametric Bayesian Dirichlet process regression (DPR) model (used by TIGAR[8]), have

trained gene expression imputation models using the same Genotype-Tissue Expression (GTEx)[9]

V8 reference data of 48 human tissue types. The Religious Orders Study (ROS)[10], Rush Memory

and Aging Project (MAP)[10], and the GTEx[9] V8 project all profile transcriptomic data of

prefrontal cortex (PFC) brain tissue and genome-wide genetic data of the same samples,

providing multiple reference panels of PFC tissue for TWAS. Thus, leveraging multiple trained

gene expression imputation models of the same target gene across multiple regression methods,

reference panels, and tissue types is expected to improve TWAS power, for more robustly

modeling the unknown genetic architecture of the target gene expression by multiple regression

models, having an increased training sample size with multiple reference panels, or borrowing

strength across multiple tissue types with correlated gene expression.

Multi-tissue approaches that can take advantage of transcriptomic reference data for multiple

tissues and/or reference panels have been developed. For example, UTMOST uses group LASSO

penalized multivariate regression to impute cross-tissue expression[11]. SWAM estimates a vector

of weights for input expression imputation models such that the weighted average of the input

models will give the least square error with respect to individual-level reference expression of

the target tissue[12]. However, these approaches have drawbacks such as being computationally

expensive and user-unfriendly. UTMOST requires individual-level reference data for all tissues.

In order to control for multicollinearity, a regularization parameter is considered by SWAM, and

needs to be fine-tuned based on the covariance structure of Genetically Regulated gene

eXpression (GReX) of all considered tissues which needs to be derived by using individual-level

transcriptomic data[12]. Additionally, SWAM requires that trained model input must be in the

same SQL database format as used for PrediXcan output[12].

To fill in this gap, we develop a novel TWAS method to leverage multiple summary-level gene

expression imputation models (i.e., base models) trained for the same target gene by the

ensemble machine learning technique of stacked regression[13,14]. We refer to this novel TWAS

method as Stacked Regression based TWAS (i.e., SR-TWAS). SR-TWAS first uses a validation

transcriptomic dataset of the target tissue type to optimally train a set of weights for the multiple

expression imputation base models per target gene (Stage I), by optimizing the gene expression

prediction R^2 (i.e., the squared correlation between observed and predicted gene expression

levels by the weighted average of multiple base models) in the validation dataset. Then SR-

TWAS takes the weighted average eQTL effect sizes as the corresponding variant weights for

gene-based association tests in Stage II. The trained expression imputation models by SR-TWAS

are specific for the tissue type of the validation data, and the identified TWAS risk genes are

interpreted with potential genetic effects mediated through the corresponding gene expression of

the tissue type of the validation data.

With comprehensive simulation studies, we showed that expression imputation models trained

by SR-TWAS had higher prediction accuracy and led to higher TWAS power than base models

across all considered scenarios. SR-TWAS achieves the greatest gains in power over base

models under scenarios in which a gene has a relatively higher proportion of true causal eQTL

with relatively smaller eQTL effect sizes. In the real data validation and application studies using

ROS/MAP and GTEx V8 reference panels and GWAS summary data of Alzheimer's disease

(AD) dementia and Parkinson's disease (PD), SR-TWAS also outperformed base models trained

using single reference panels and tissue types.

In the following sections, we first briefly describe the stacked regression method used by SR-

TWAS. Then we describe the results of our simulation studies, validation studies using the real

ROS/MAP and GTEx V8 reference panels, as well as application TWAS of AD dementia and

PD. Last, we end with a discussion.

Results

Overview of SR-TWAS

In the framework of TWAS[7,8,15], a multivariable linear regression model is assumed for training

gene expression imputation model, taking quantitative gene expression levels E_g of the target

gene and tissue as the response variable and cis-acting genetic variants nearby the target gene

region (genotype matrix G) as predictors, as shown in the following formula:

$$E_g = Gw + \epsilon, \qquad \epsilon_i \sim N(0, 1).$$

The eQTL effect sizes w could be trained by different regression methods and/or using different

reference panels.

Assume there are a total of K base gene expression imputation models trained for the same target

gene, with $\widehat{w_k}, k = 1, \dots, K$. Let $\mathbf{E}_{vg}$ denote the gene expression levels of the target gene g in the

target tissue type in the validation data, and $\mathbf{G}_v$ denote the genotype matrix of the same genetic

predictors in the validation data. Then the predicted GReX of the validation samples by the kth

base model are given by $\mathbf{G}_v \widehat{\mathbf{w}}_k$. The stacked regression method[13,14] will solve for a set of optimal

base model weights $\zeta_1, \dots, \zeta_K$, by maximizing the regression R^2 between the profiled gene

expression $\mathbf{E}_{vg}$ and the weighted average GReX, $\sum_{k=1}^{K} \zeta_k \, \mathbf{G}_v \widehat{\mathbf{w}}_k$, of K base models, i.e.,

minimizing the following loss function of $1 - R^2$:

$$\text{minimize}_{(\zeta_k; \, k=1,\dots,K)} \frac{\left\| \mathbf{E}_{vg} - \sum_{k=1}^{K} \zeta_k \, \mathbf{G}_v \widehat{\mathbf{w}}_k \right\|^2}{\left\| \mathbf{E}_{vg} - E_{vg} \right\|^2}, \quad \text{s.t.} \sum_{k=1}^{K} \zeta_k = 1, \, \zeta_k \in [0,1].$$

As a result, we will obtain a set of model weights ζ_k for $k = 1, \dots, K$ base models, and a set of

eQTL effect sizes $\widetilde{\mathbf{w}}$ given by the weighted average of the eQTL effect sizes of K base models,

$\widetilde{\mathbf{w}} = \sum_{k=1}^{K} \zeta_k \, \widehat{\mathbf{w}}_k$ (Stage I). Then the final predicted GReX for test genotype data $\mathbf{G}_t$ is given by

$\widehat{\text{GReX}}_g = \mathbf{G}_t \widetilde{\mathbf{w}}$, and $\widetilde{\mathbf{w}}$ will be taken as variant weights in the gene-based association tests by

SR-TWAS in Stage II. Genes with 5-fold cross validation (CV) $R^2 > 0.5\%$ in the validation

dataset by SR-TWAS are considered as having a valid imputation model and will be tested in

Stage II[8]. Here, $\widetilde{\mathbf{w}}$ is the trained eQTL effect sizes by SR-TWAS (Stage I) for the target gene of

the tissue of the validation data, and identified significant genes from Stage II have potential

genetic effects mediated through the transcriptome of the tissue of the validation data.

Simulation Studies

By simulation studies, we compared the performance of SR-TWAS with a Naïve approach which

takes the average of base models as the trained gene expression imputation model, that is, taking

$\zeta_k = \frac{1}{K}, k = 1, \dots, K$. We used the real genotype data of gene *ABCA7* from ROS/MAP and GTEx

V8 to simulate gene expression and phenotypes, and considered multiple scenarios with varying

proportions of causal SNPs ($p_{causal} = (0.001, 0.01, 0.05, 0.1)$) and gene expression heritability

(i.e., the proportion of gene expression variation due to genetics, $h_e^2 = (0.1, 0.2, 0.5)$). We

randomly selected n=465 training samples with Whole Genome Sequencing (WGS) genotype

data from the ROS/MAP cohort and GTEx V8 cohort, respectively. We randomly selected

n=400 and n=800 samples with WGS genotype data from ROS/MAP as our validation and test

cohorts, respectively. Training, validation, and test samples from the ROS/MAP cohort were

simulated with the same causal SNPs (i.e., eQTL), while training samples from the GTEx V8

cohort were simulated with true causal SNPs that were 50% overlapped with the ones for

ROS/MAP samples. The simulated expression heritability was the same for both ROS/MAP and

GTEx V8 samples.

Two base models per gene were trained by PrediXcan (penalized regression with Elastic-Net

penalty) with the GTEx training samples (n=465), and by TIGAR (nonparametric Bayesian

Dirichlet process regression) with the ROS/MAP training samples (n=465). SR-TWAS and

Naïve models were then obtained by using these trained base models. Validation data ($n = 400$)

were used to train SR-TWAS models. Gene expression imputation models (by SR-TWAS and

Naïve methods) with 5-fold cross-validation $R^2 > 0.5\%$ in the validation cohort were considered

valid models and used for follow-up gene-based association tests. Test data (n=800) were used

for assessing GReX prediction performance and TWAS power, with 1,000 repeated simulations

per scenario. We compared the performance of SR-TWAS, Naïve method, and these two base

models.

As shown in **Fig. 1**, we showed that SR-TWAS obtained the highest test R^2 for gene expression

imputation across all scenarios, with slightly better performance than the base models trained by

TIGAR with ROS/MAP samples (TIGAR_ROSMAP), by leveraging the predictive information

provided by both base models. Both SR-TWAS and the TIGAR_ROSMAP base models

performed better than the Naïve method. The base models trained by PrediXcan with GTEx

samples (PrediXcan_GTEx) performed the worst. This is because all ROS/MAP training,

validation, and test samples are simulated under the same causality model with the same set of

causal SNPs, while GTEx training samples were simulated only with 50% overlapped true causal

SNPs of the validation and test samples. The Naïve approach of taking averages of the base

models had poor performance because of the heterogeneous genetic architecture between the

GTEx training cohort and test cohort. As expected, model performance improved with increasing

true expression heritability h_e^2 with the same training sample size. For all considered scenarios,

the highest test R^2 were obtained under a sparse causality model with $p_{\text{causal}} = 0.001$, where true

causal SNP effect sizes would be relatively larger given the same h_e^2. CV R^2 and training R^2

results for Naïve and SR-TWAS approaches for these scenarios (Supplementary Figures 1-2)

also showed that SR-TWAS outperformed the Naïve approach under all scenarios.

In order to assess TWAS power, phenotypes were simulated with a certain proportion of

variance due to simulated gene expression (h_p^2). We considered a series of h_p^2 values in the range

of $(0.05, 0.875)$. The TWAS power comparison by SR-TWAS, naïve method, and two base

models were shown in **Fig. 2**, where the results were consistent with the test R^2 comparison as in

Fig 1. SR-TWAS performed similarly to the TIGAR_ROSMAP base model, while the Naïve

method performed worse than SR-TWAS and TIGAR_ROSMAP base model but still better than

the PrediXcan_GTEx base model. In particular, SR-TWAS had a noticeable advantage over the

TIGAR_ROSMAP model with $p_{\text{causal}} = 0.01$ and $h_e^2 = 0.5$. Although desirable TWAS power

~80% was only obtained in simulation scenarios with a relatively high h_p^2 that might be higher

than the value in real studies, simulation power would increase along with increased test sample

sizes. Because real GWAS test data would have a larger sample size than the 800 considered in

our simulations, we expect desirable power for our SR-TWAS method in real studies.

Additionally, we conducted similar simulation studies for two other settings, where samples from

ROS/MAP and GTEx cohorts have the same set of true causal SNPs (i.e., the same genetic

architecture), and (i) the expression heritability was the same for both ROS/MAP and GTEx V8

cohorts, or (ii) the expression heritability for GTEx V8 cohort is only half that of ROS/MAP.

The results of these settings were similar to that of the previously described setting. SR-TWAS

and TIGAR_ROSMAP models outperformed the PrediXcan-GTEx and Naïve methods.

Comparisons of CV R^2 and training R^2 for Naïve and SR-TWAS approaches for these scenarios

(Supplementary Figures 3, 4, 7, and 8) showed that SR-TWAS outperformed the Naïve approach

under all scenarios. For all considered scenarios, again the highest test R^2 was obtained under a

sparse causality model with high expression heritability (Supplementary Figures 5 and 9). Power

comparison results show that SR-TWAS and TIGAR_ROSMAP models generally outperformed

the PrediXcan-GTEx and Naïve methods (Supplementary Figures 6 and 10), particularly in the

setting in which the expression heritability for GTEx V8 cohort was only half that of ROS/MAP

(Supplementary Figure 10).

We also assessed type I error under the example scenario with $p_{\text{causal}} = 0.1$, $h_e^2 = 0.1$. Base

model weights were permuted 10^6 times and used to train SR-TWAS and Naïve models, which

were then used to conduct gene-based association tests with a phenotype generated randomly

from $N(0, 1)$. All methods control well for type I errors for significance thresholds

$(10^{-4}, 10^{-5}, 2.5 \times 10^{-6}, 10^{-6})$, as shown in Supplementary Table 1. Type I errors for Naïve

method were comparable to that of the base models, while SR-TWAS had the lowest type I error

under all significance thresholds.

Real Validation Studies

To compare the GReX prediction accuracy with real gene expression data, we considered three

base models that were trained by TIGAR with ROS samples (n=237, TIGAR_ROS_DLPFC) for

dorsolateral prefrontal cortex (DLPFC) tissue, trained by TIGAR with GTEx V8 data of the

brain frontal cortex tissue[8] (n=157, TIGAR_GTEx_BRNCTXB), and trained by PrediXcan with

the same GTEx reference data of brain frontal cortex tissue (n=157,

PrediXcan_GTEx_BRNCTXB)[7]. SR-TWAS (SR-TWAS_MAP_DLPFC) and Naïve

(Naive_MAP_DLPFC) models were trained from these three base models with respect to a

validation dataset with half MAP samples (n=114, randomly selected) of DLPFC tissue. Valid

gene expression imputation models trained by SR-TWAS and Naïve methods with 5-fold CV

$R^2 > 0.5\%$ in validation data were tested using the other half MAP samples (n=114) of DLPFC

tissue.

By comparing test R^2 obtained by SR-TWAS, Naïve, and three base models (Supplementary

Table 2), we showed that PrediXcan_GTEx_BRNCTXB had the highest median (0.070) and

mean (0.113) test R^2 but only for 867 valid gene expression imputation models, SR-TWAS had

the second highest median (0.026) and mean (0.068) test R^2 for 8425 valid genes expression

imputation models, and Naïve model performed similarly as SR-TWAS but with a slightly lower

median (0.025) and mean (0.065) test R^2 and fewer valid genes expression imputation models

(8360). By pair-wise comparison of test R^2 for all genes with valid expression imputation

models as shown in Supplementary Figure 11, SR-TWAS (y-axis) performed noticeably better

than Naïve and three base models (x-axis).

Application TWAS of AD Dementia

Training expression imputation models of SMA tissue by SR-TWAS

We considered four base models — TIGAR and PrediXcan models trained with 465 ROS/MAP

samples of DLPFC tissue (TIGAR_ROSMAP_DLPFC, PrediXcan_ROSMAP_DLPFC), TIGAR

and PrediXcan models trained with 157 GTEx V8 samples of prefrontal cortex tissue

(TIGAR_GTEx_BRNCTXB, PrediXcan_GTEx_BRNCTXB). Additional 76 ROS/MAP samples

of the supplementary motor area (SMA) brain tissue were used as the validation dataset to train

SR-TWAS models and to calculate the 5-fold CV R^2 that was used to select genes with valid

imputation models. Here, we compared SR-TWAS to base models trained by two different

regression methods as used by TIGAR and PrediXcan, as well as models trained by TIGAR

using the validation data of the target SMA brain tissue (TIGAR_ROSMAP_SMA), to show the

advantages of SR-TWAS about leveraging multiple regression models, reference panels, and

multiple tissues.

By comparing the CV R^2 and numbers of genes with valid expression imputation models

obtained by SR-TWAS and 4 base models (**Table 1**), we found that gene expression imputation

models trained by SR-TWAS for the SMA tissue (SR-TWAS_ROSMAP_SMA) had the highest

median CV R^2 (~0.07) and second highest mean CV R^2 (0.09) for ~20K genes with valid

expression imputation models. Although the PrediXcan_GTEx_BRNCTXB base model had third

highest median CV R^2 (0.061) and highest mean CV R^2 (0.10), but only for 4563 genes with

valid expression imputation models. The TIGAR_ROSMAP_SMA models with the lowest

sample size of the single-cohort models (n=76), had the greatest number of trained genes

(32350), second highest median CV R^2 (0.064), and second highest mean CV R^2 (0.076), which

is consistent with overfitting trends in model training as observed in previous studies[8]. These

results showed that improved CV R^2 in a real validation cohort of SMA tissue was obtained by

SR-TWAS, by leveraging multiple regression methods from two reference panels of multiple

relevant tissues (DLPFC and frontal cortex tissues).

TWAS results of AD dementia

By using the eQTL weights obtained by SR-TWAS using the above four base models and SMA

validation data and TIGAR models trained using the SMA validation data, we conducted TWAS

with the summary-level data of the most recent GWAS of AD dementia (n=~762K)[16]. SR-

TWAS identified a total of 56 significant TWAS risk genes of AD dementia with p-values <

2.5×10^{-6}. Of these, 17 are known GWAS risk genes, 39 are within 1MB of a known GWAS

risk gene, and 19 have been previously identified as TWAS risk genes of AD dementia[17–22]

(Supplementary Table 3).

Because TWAS considers genotype data within a $\pm$1MB region of a test gene, nearby significant

TWAS genes with overlapping test regions often have correlated GReX values and might not

represent independent associations. We curated 11 independent TWAS risk genes of AD from

these 56 significant genes (**Table 2, Fig. 3**), by selecting the most significant gene as the

independent risk gene for a cluster of significant genes with overlapped test regions. We found

that 6 of these independent risk genes were novel TWAS risk genes (*AC073842.1, DMPK,*

FAM13C, GFAP, PPP1R9B , and *SLC15A3*), 4 were known GWAS risk genes (*ACE*[18,23,24],

CR1[16,18,19,24,25], *HLA-DRA*[19,24], and *TREM2*[16,19,24,26]), and 5 were previously identified as TWAS

risk genes (*ACE*[17], *CR1*[17], *HLA-DRA*[18], *TREM2*[21], and *ZSCAN26*[18]). Importantly, 3 out of these

11 independent risk genes were also identified by TIGAR with ROSMAP SMA validation data

(TIGAR_ROSMAP_SMA). Compared to the TWAS results using individual base models

(Supplementary Figure 12), both SR-TWAS and TIGAR_ROSMAP_SMA models identified a

greater number of independent risk genes.

Interestingly, *ACE* is a protein-coding gene involved in the regulation of blood pressure and

cerebral blood flow. Gene *CR1* encodes a complement system protein that may play a role in

amyloid beta (an important AD pathology) clearance[25], which was also identified by previous

Mendelian randomization studies[18]. Gene *HLA-DRA* is located in the major histocompatibility

complex region that is expressed in glial cells[27] and which has also been previously identified by

eQTL analysis[19]. Gene *TREM2*, which encodes membrane receptor in microglia and other

immune cells and may be related to chronic inflammation[26], is also a known risk gene of AD

identified by eQTL colocalization[24]. Gene *ZSCAN26*, near the known GWAS risk gene *OR2B2*[28]

and identified by previous TWAS[18], is a protein-coding gene predicted to be involved in DNA-

binding of transcription factors and regulation of transcription.

The other 6 independent significant TWAS risk genes (*AC073842.1*, *DMPK*, *FAM13C*, *GFAP*,

PPP1R9B, and *SLC15A*) identified by SR-TWAS are within 1MB of known GWAS risk

genes[16,18,19,24,28,29], with the former 5 also being within 1MB of a previously identified TWAS

risk gene[17,18] and the latter identified by TWAS[18]. *AC073842.1* is a long non-coding RNA gene

located near GWAS risk gene *AP4M1*[18] (also identified by SR-TWAS as a significant TWAS

risk gene), and known TWAS risk gene *PMS2P1*[17]. SR-TWAS also identified 8 other genes in

this region (see Supplemental Table 3), all of which were also within 1MB of *PMS2P1*. *DMPK*

was the most significant association of a cluster of 29 genes in the same overlapped test region

identified by SR-TWAS, whose test region overlaps with the well-known GWAS risk gene

APOE[16,18,19,23,25,28]. A pathogenic repeat expansion in a noncoding region of *DMPK* causes

myotonic dystrophy 1 (DM1), a multi-system disease which includes brain involvement[30].

Studies of brain pathology in DM1 patients have found associations between *DMPK* and the AD-

related genes *MAPT*, *APP*, and *SNCA*[30]. *FAM13C* is a protein-coding gene which has been found

to be an independent prognostic marker in prostate cancer[31], a malignancy associated with AD[32].

The protein product of *GFAP* is expressed on glial cells and has been used as a biomarker of

astrocyte activation and inflammation[27,33]. Multiple studies of *GFAP* note its potential as a

prognostic biomarker for predicting future dementia[33]. Pereira, et al found that plasma levels of

GFAP protein had greater performance as a predictive biomarker of amyloid-β positivity than the

TREM2 protein[33]. *PPP1R9B* encodes the protein spinophilin that is expressed in dendritic spines

and linked to AD progression[34,35]. Further, mouse models of AD have found *TREM2* to be an

important regulator of spinophilin expression[36].

Additionally, *SLC15A3* is located in the AD-associated *MS4A* gene cluster[29], which contains

multiple known GWAS risk genes[16,18–20] as well as TWAS risk gene *MS4A2*[17] of AD. The *MS4A*

gene cluster is notable due its role in the regulation of soluble *TREM2* in cerebrospinal fluid in

AD[29]. *SLC15A3* encodes a protein that enables transmembrane transport of histidine and di-

/tripeptides across cell membranes and may play a role in the innate immune response and

inflammation[37]. It has been recently identified as a differentially expressed gene in AD[22].

Application TWAS of PD

Training expression imputation models of brain substantia nigra tissue by SR-TWAS

We considered six base models trained by TIGAR on six different tissues from GTEx V8 —

brain anterior cingulate cortex BA24 (BRNACC) (n=136), brain caudate basal ganglia

(BRNCDT) (n=173), brain cortex (BRNCTXA) (n=184), brain nucleus accumbens basal ganglia

(BRNNCC) (n=182), brain putamen basal ganglia (BRNPTM) (n=154), and whole blood

(BLOOD) (n=574). An additional 101 GTEx samples of brain substantia nigra (BRNSNG) tissue

were used as the validation data to train SR-TWAS models and to calculate the 5-fold CV R^2

that was used to select genes with valid expression imputation models. TIGAR models were also

trained on the validation data of brain substantia nigra tissue (TIGAR_GTEx BRNSNG) to

compare TWAS results with that of SR-TWAS.

TWAS Results of PD

Besides AD, we also conducted TWAS using GWAS summary statistics by the most recent

biggest studies of PD (n=~33K cases, ~18k UK Biobank proxi-cases, and ~828K controls)[38],

where the eQTL weights obtained by the above SR-TWAS models based on six base models of

multiple tissues and validation data of brain substantia nigra tissue and

TIGAR_GTEx_BRNSNG models were used. As a result, SR-TWAS identified a total of 62

significant TWAS risk genes of PD. Of these, 15 are known GWAS risk genes, 42 are within

1MB of a known GWAS risk gene, and 17 have been previously identified as TWAS risk genes

of PD (Supplementary Table 4).

Similarly, from these 62 risk genes, we curated 12 independent TWAS risk genes of PD (**Fig. 4;**

Table 3), including 5 novel TWAS risk genes (*IDUA*, *LA16c-385E7.1*, *LRRC37A4P*,

SHROOM3, and *SLC30A3*). Of these novel TWAS risk genes, three (*IDUA*, *LRRC37A4P*,

SHROOM3) are near known GWAS risk genes (*GAK*[38]*, FAM47E*[38], *MAPT*[38]). The other 7

known TWAS risk genes were also known GWAS risk genes (*CD38*[39,40], *GPNMB*[38,40],

MMRN1[38,39], *NDUFAF2*[38], *RAB29*[38,40], *VKORC1,* and *ZSWIM7*[39]). Importantly, 2 of these

independent significant TWAS risk genes (*GPNMB*[38,40], *MMRN1*[38,39]) were also identified by the

TIGAR_GTEx_BRNSNG models. Compared to the TWAS results using these six base models

(Supplementary Figure 13), SR-TWAS models still identified the greatest number of

independent risk genes while the TIGAR_GTEx_BRNSNG models identified the fewest.

Defects in *IDUA* are known to cause the lysosomal storage disorder Hurler syndrome; lysosomal

mechanisms are thought to play a role in PD pathogenesis; and lysosomal storage disorder gene

variants have been associated with increased PD risk[41]. *NDUFAF2* encodes for a component of

mitochondrial complex I and loss of its functionality results in a rare mitochondrial

encephalopathy with frequent substantia nigra pathology and motor symptoms[42]. *NDUFAF2* was

also identified as a potential drug target in a Mendelian randomization study of potential drug

targets for PD treatment[43]. *SHROOM3* is involved in neural tube development, cell shape, and

epithelial morphogenesis and variants which alter its expression have been implicated in chronic

kidney disease[44], which shares pathophysiological mechanisms with PD and has been shown to

increase PD risk[45]. Synaptic $Zn2+$ has been implicated in the pathophysiology of PD and the

only known transporter of $Zn2+$ into synaptic vesicles, ZnT3, is the protein product of

SLC30A3[46]. *ZSWIM7* has been identified as a TWAS risk gene[39]. The protein product of

VKORC1 is an important component of normal blood coagulation and is targeted by the

anticoagulant drug warfarin[43]. *VKORC1* was also identified by Mendelian randomization as a

potential drug target in PD treatment[43].

LRRC37A4P is a pseudogene near a known TWAS risk gene *LRRC37A2*[39] (also identified by

SR-TWAS). *CD38* is involved in neurodegeneration, neuroinflammation, and aging[39,47].

GPNMB codes for a glycoprotein observed upon tissue damage and inflammation[48], and the

GPNMB protein has been found to be elevated in PD patients after lysosomal stress[48]. *MMRN1* is

a carrier protein for platelet factor V and lies ~84KB downstream of a well-established GWAS

risk locus found in multiple populations[38]. *RAB29* has been implicated as a regulator of PD-

associated *LRRK2*[49].

Discussion

We present a novel TWAS tool (SR-TWAS) using the ensemble machine learning technique of

stacked regression [13,14,50], for leveraging multiple gene expression imputation models trained by

different regression methods and/or using different transcriptomic reference panels of different

tissue types. We demonstrated the advantages of SR-TWAS through comprehensive simulation

studies, testing gene expression prediction accuracy in real data, and real TWAS of AD dementia

and PD. We showed that SR-TWAS outperformed the Naïve method, base models, and models

trained using a single reference panel of the target tissue, especially when base models are

trained by diverse regression methods and reference panels of different tissue types. Our results

show similar strength to previous studies using stacked regression in other fields[14].

Especially, in the real application TWAS of AD dementia and PD, SR-TWAS identified a

greater number of total independent risk genes than any of the base models and similar or greater

number than models trained using a single reference panel of the target tissue. Besides known

GWAS/TWAS risk genes, or nearby known GWAS/TWAS risk genes, that were identified by

SR-TWAS, we also found 6 novel independent TWAS risk genes for AD dementia and 6 novel

independent TWAS risk genes for PD with known functions in respective disease pathology.

Additionally, we found interesting biological interpretations relevant to AD dementia and PD for

our identified TWAS risk genes. These application TWAS results indeed showed the robust and

practical useful performance of our SR-TWAS tool.

The SR-TWAS tool, including the Naïve method as an option, is publicly available on GitHub.

The SR-TWAS tool implements user-friendly features, including accepting genotype data of

standard VCF-format as input, enabling parallel computation, and using efficient computation

strategies to reduce time and memory usage. The most computation expensive part is to train all

base models with different reference panels, which is subject to the regression method. For

example, with training sample size n=465, PrediXcan (Elastic-Net) costs ~1 CPU minute and

TIGAR (DPR) costs ~3 CPU minutes in average per gene. Publicly available trained models can

also be used as base models by the SR-TWAS tool. The process of training SR-TWAS models

from base models and validation data is quite computational efficient. For example, with the

ROS/MAP SMA tissue validation dataset (n=76) and four base models in our real studies, SR-

TWAS model training costs ~15 CPU seconds per gene. With the GTEx substantia nigra tissue

validation dataset (n=101) and six base models in our real studies, SR-TWAS model training

costs ~103 CPU seconds per gene.

SR-TWAS still has its limitations. For example, SR-TWAS only considers cis-eQTL during

model training, uses the standard two-stage TWAS, requires an additional validation dataset of

the target tissue independent of those used for base model training[14], and assumes samples of the

validation dataset and test GWAS cohort are of the same ancestry[51]. Previous studies have

illustrated the importance of considering both cis- and trans- eQTL in TWAS[52], and a joint

modeling of the gene expression imputation and the gene-based association test[53 54]. The stacked

regression technique used by SR-TWAS also applies to scenarios considering both cis- and

trans- eQTL, when base models trained with both cis- and trans- eQTL are available. Using the

recently developed variance component gene-based association test[55] in Stage II is expected to

help account for the uncertainty of eQTL effect sizes estimation in the reference panel, a

common issue for the two-stage TWAS methods.

Overall, the SR-TWAS tool provides a useful resource for researchers to take advantages of the

publicly available gene expression imputation models by using multiple regression methods

(e.g., PrediXcan[7], FUSION[15], TIGAR[8]) and different reference panels of multiple tissue types

(e.g., ROS/MAP[10], GTEx[9]). In particular, the final trained gene expression imputation model by

SR-TWAS will be with respect to the same tissue type as the validation data set. Because

multiple base models would not only increase the robustness of the gene expression imputation

model but also increase the total effective training sample size, SR-TWAS is expected to further

increase TWAS power for studying complex human diseases.

Acknowledgements

RP and JY are supported by National Institutes of Health (NIH/NIGMS) grant award

R35GM138313. MPE was supported by NIH/NIGMS grant award R01GM117946 and NIH/NIA

grant award RF1AG071170. ROS/MAP study data were provided by the Rush Alzheimer's

Disease Center, Rush University Medical Center, Chicago, IL. Data collection was supported

through funding by NIA grants P30AG10161, R01AG15819, R01AG17917, R01AG30146,

R01AG36836, R01AG56352, U01AG32984, U01AG46152, U01AG61356, the Illinois

Department of Public Health, and the Translational Genomics Research Institute.

Table 1. Comparison of CV R^2 of SMA tissue for valid gene expression imputation models
 trained by SR-TWAS, TIGAR with validation data, and four base models with ROS/MAP
 and GTEx V8 reference panels of DLPFC tissue.

	Sample Size	Median CV R^2	Mean CV R^2	N_{genes}
PrediXcan_GTEx_BRNCTXB[a]	157	0.061	0.100	4563
PrediXcan_ROSMAP_DLPFC[a]	465	-	-	6532
TIGAR_GTEx_BRNCTXB[a]	157	0.038	0.065	21921
TIGAR_ROSMAP_DLPFC[a]	465	0.016	0.048	11981
TIGAR_ROSMAP_SMA	76	0.064	0.076	32350
SR-TWAS_SMA	-	0.072	0.090	20216

 a base model used by SR-TWAS

 Table 2. Independent TWAS risk genes of AD dementia identified by SR-TWAS.

				SR-TWAS SMA		TIGAR SMA	
Gene	CHR	Start	End	Zscore	Pvalue	Zscore	Pvalue
CR1[ac]	1	207496147	207641765	-7.30	2.91e-13	-2.64	8.17e-03
ZSCAN26[bc]	6	28267010	28278224	4.71	2.50e-06	-3.56	3.69e-04
HLA-DRA[ac]	6	32439878	32445046	-6.88	5.93e-12	-0.00	9.98e-01
TREM2[ac]	6	41158506	41163186	5.42	6.05e-08	4.00	6.38e-05
AC073842.1[bd]	7	100130964	100140439	5.86	4.54e-09	-5.09	3.65e-07
FAM13C[bd]	10	59246130	59363181	-4.87	1.13e-06	3.49	4.83e-04
SLC15A3[bd]	11	60937084	60952530	-7.57	3.82e-14	-4.74	2.11e-06
GFAP[bd]	17	44903159	44916937	-4.73	2.21e-06	-1.03	3.05e-01
PPP1R9B[bd]	17	50133737	50150677	5.11	3.15e-07	-3.59	3.25e-04
ACE[ac]	17	63477061	63498380	5.05	4.44e-07	-1.66	9.69e-02
DMPK[bd]	19	45769717	45782552	16.52	2.79e-61	-11.18	5.21e-29

 a known GWAS risk gene of AD.
 b gene within 1MB of known GWAS risk gene of AD.
 c previously identified TWAS risk gene of AD.
 d gene within 1MB of previously identified TWAS risk gene of AD.

430 **Table 3. Independent TWAS risk genes of Parkinson's disease identified by SR-TWAS.**

Gene	CHR	Start	End	SR-TWAS BRNSNG		TIGAR BRNSNG	
				Zscore	Pvalue	Zscore	Pvalue
RAB29^{ac}	1	205767986	205775460	-5.30	1.17e-07	-4.17	3.06e-05
SLC30A3	2	27254572	27275817	-4.95	7.56e-07	-0.74	4.62e-01
IDUA^{bd}	4	986997	1004506	5.77	7.98e-09	4.05	5.09e-05
CD38^{ac}	4	15778275	15853230	7.68	1.57e-14	2.10	3.59e-02
SHROOM3^{bd}	4	76435100	76783253	5.17	2.32e-07	1.85	6.48e-02
MMRN1^{ac}	4	89879532	89954629	-7.91	2.55e-15	-8.50	1.95e-17
NDUFAF2^{ac}	5	60945129	61153037	-5.45	4.91e-08	-3.71	2.10e-04
GPNMB^{ac}	7	23235967	23275108	-5.52	3.31e-08	-5.11	3.28e-07
LA16c-385E7.1	16	1512979	1514675	-4.81	1.50e-06	-2.40	1.64e-02
VKORC1^{bc}	16	31090842	31095980	-5.56	2.75e-08	-3.60	3.22e-04
ZSWIM7^{c}	17	15976560	15993830	-5.32	1.04e-07	-4.13	3.59e-05
LRRC37A4P^{bd}	17	45506741	45550335	-9.41	4.98e-21	-9.13	6.85e-20

431 *a* known GWAS risk gene of PD.
432 *b* gene within 1MB of known GWAS risk gene of PD.
433 *c* previously identified TWAS risk gene of PD.
434 *d* gene within 1MB of previously identified TWAS risk gene of PD.
435
436

Figures

Figure 1. Boxplots of gene expression prediction R^2 for simulations with varying
proportion of true causal SNPs $p_{\text{causal}} = (0.001, 0.01, 0.05, 0.1)$ and true expression
heritability $h_e^2 = (0.1, 0.2, 0.5)$. SR-TWAS performed comparably as the TIGAR_ROSMAP
base model, but consistently better than the Naïve and PrediXcan_GTEx base models. This is
because test samples are simulated under the same genetic architecture as the ROSMAP training
cohort used by TIGAR_ROSMAP and the validation cohort used by SR-TWAS, which only
have 50% overlapped true causal SNPs as the GTEx training cohort used by PrediXcan_GTEx.

Figure 2. Power comparison for simulations with varying proportion of true causal SNPs $p_{\text{causal}} = (0.001,\ 0.01,\ 0.05,\ 0.1)$**, true expression heritability** $h_e^2 = (0.1,\ 0.2,\ 0.5)$**, and phenotype heritability** $h_p^2 \in (0.05, 0.875)$**.** SR-TWAS performed comparably as the TIGAR_ROSMAP base models trained using ROSMAP training cohort, but consistently better than the Naïve method and PrediXcan_GTEx base models trained using GTEx training cohort. This is because test samples are simulated under the same genetic architecture as the ROSMAP training cohort and the validation cohort used by SR-TWAS, which only have 50% overlapped true causal SNPs as the GTEx training cohort.

Figure 3. Manhattan plots of TWAS results by SR-TWAS and TIGAR models trained for the target SMA tissue for studying AD dementia. TIGAR models were trained using the validation data as used by SR-TWAS method. A total of 56 (11 independent) TWAS risk genes were identified by SR-TWAS, and 3 out of these 11 independent genes were also identified by TIGAR models. Significant genes are shown in orange and significant genes that are labeled and discussed in the text are shown in red.

Figure 4. Manhattan plots of TWAS results by SR-TWAS and TIGAR models trained for the target substantial nigral tissue for studying Parkinson's Disease. TIGAR models were trained using the validation data as used by SR-TWAS method. A total of 62 (12 independent) significant TWAS risk genes were identified by SR-TWAS, and 3 of these 12 independent genes were also identified by TIGAR models. Significant genes are shown in orange and significant genes that are labeled and discussed in the text are shown in red.

Methods

SR-TWAS using Stacked Regression

Stacked regression is a machine learning method for forming optimal linear combinations of different predictors to improve prediction accuracy[14]. The theoretical background for combining predictors rather than selecting a single best predictor is well-established and has been developed since the 1970s[14,56,57]. The "stacking" method of combining predictors originated in a 1992 paper[13] by Wolpert, who described the concept as any scheme for feeding information from a set of cross-validated models to another before forming the final prediction in order to reduce prediction error[13]. The idea is further expanded with stacked regression, a specific framework for combining the initial predictors by weighted average with coefficient constraints to control for multicolinearity[14].

In standard two-stage TWAS, we need to first fit a gene expression imputation model, which is assumed as a multivariable linear regression model, with quantitative gene expression levels E_g for the target gene and tissue type as the response variable, and genotype matrix G of nearby/genome-wide SNPs as predictors,

$$E_g = Gw + \epsilon, \qquad \epsilon_i \sim N(0, 1).$$

This gene expression imputation model can be trained per gene per tissue type, using a transcriptomic reference panel which profiles both transcriptomic and genetic data of the same training cohort. SNPs with non-zero effect sizes w are referred to as a broad sense of eQTL. The eQTL effect sizes w will be estimated from each trained model by different regression methods and/or using different reference data of multiple tissue types.

Assume there are a total of K base gene expression imputation models that are trained for the same target gene and tissue type, with $\widehat{w_k}, k = 1, \dots, K$, as the trained eQTL effect sizes per base

model. Let $\mathbf{E}_{vg}$ denote the gene expression levels of the same target gene g and tissue type in the

validation data, and $\mathbf{G}_v$ denote the genotype matrix of the same genetic predictors in the

validation data. Then the predicted Genetically Regulated gene eXpression (GReX) of the

validation samples are given by $\mathbf{G}_v \widehat{\mathbf{w}}_k$, by the kth base model. The stacked regression

method[13,14] will solve for a set of optimal model weights $\zeta_1, \dots, \zeta_K$, by maximizing the regression

R^2 between the profiled gene expression $\mathbf{E}_{vg}$ and the weighted average GReX, $\sum_{k=1}^{K} \zeta_k \mathbf{G}_v \widehat{\mathbf{w}}_k$, of

K base models, ie, minimizing the following loss function of $1 - R^2$:

$$\text{minimize}_{(\zeta_k; \, k=1,\dots,K)} \frac{\left\| \mathbf{E}_{vg} - \sum_{k=1}^{K} \zeta_k \mathbf{G}_v \widehat{\mathbf{w}}_k \right\|^2}{\left\| \mathbf{E}_{vg} - E_{vg} \right\|^2}, \quad \text{s.t.} \sum_{k=1}^{K} \zeta_k = 1, \; \zeta_k \in [0,1].$$

As a result, we will obtain a set of model weights ζ_k for $k = 1, \dots, K$ base models, and a set of

eQTL effect sizes $\widetilde{\mathbf{w}}$ given by the weighted average of the eQTL effect sizes of K base models,

$\widetilde{\mathbf{w}} = \sum_{k=1}^{K} \zeta_k \widehat{\mathbf{w}}_k$ (Stage I). Then the final predicted GReX for test genotype data $\mathbf{G}_t$ is given by

$\widehat{\text{GReX}}_g = \mathbf{G}_t \widetilde{\mathbf{w}}$, and $\widetilde{\mathbf{w}}$ will be taken as variant weights in the gene-based association tests by

SR-TWAS in Stage II.

Genes with 5-fold CV $R^2 > 0.5\%$ in the validation dataset by SR-TWAS are considered as

having a valid imputation model and will be tested in Stage II. That is, the validation dataset will

be randomly split into 5 folds. For each fold of data, SR-TWAS model will be trained using the

other 4-fold data and then use to calculate prediction R^2 with the current fold. The average

prediction R^2 across all 5 folds of data is considered as the 5-fold CV R^2. Here, we use a more

liberal threshold (0.005) than the threshold 0.01 used by previous studies [15,58,59] to allow more

genes to be tested in follow-up TWAS. Because the follow-up gene-based association Z-score

test statistic is essentially a weighted average of single variant GWAS Z-score statistics with

variant weights provided by the eQTL effect sizes[8], poorly estimated eQTL weights would only

reduce power but will not increase false positive rate under null hypothesis.

Naïve Method

543   In this paper, we compared SR-TWAS to a Naïve approach which just takes the average of base

544   models as the trained gene expression imputation model, that is, takes $\zeta_k = \frac{1}{K}, k = 1, \ldots, K$.

545   Using a validation dataset, we can still evaluate the validation R^2 which can be used to select

546   valid genes with validation $R^2 > 0.5\%$.

SR-TWAS Tool Framework

SR-TWAS tool was designed to be compatible with the TIGAR-V2 tool framework[8]; it accepts

models trained by TIGAR-V2 as input, imports utility functions from TIGAR-V2, and outputs

model files which can be used as input for TIGAR-V2 GReX prediction and summary-level

TWAS. Much of the structure of the SR-TWAS code was derived from existing TIGAR-V2

scripts and it shares dependencies on TABIX[60] and the Python libraries of numpy[61,62], pandas[61],

scipy[63], statsmodels[64], and scikit-learn[65,66].

The SR-TWAS script utilizes scikit-learn's consistent, extensible interfaces for defining

estimators and predictors and for initializing objects[66]. The script trains a stacked regression

model using a modified version of scikit-learn's StackingRegressor class, which trains a final

estimator from cross-validated predictions from base estimators fitted on the full design matrix.

The script defines two custom classes to be used as input for the stacking regressor object: a base

estimator class (WeightEstimator) which converts trained GReX prediction models into scikit-

learn-compatible estimator objects and a final estimator class (ZetasEstimator) which obtains the

values of $\zeta_1, \ldots, \zeta_K$ that minimize the loss function under the constraints $\zeta_k \geq 0$ and $\sum_{k=1}^{K} \zeta_k =$

1[14].

During the stacked regression, SNP minor allele frequencies and effect sizes for the specified

target are first read from each of the K user-specified weight files. The SNPs are then matched to

SNPs in the validation genotype data and filtered to exclude effect sizes of SNPs for which the

difference between the MAF of the genotype data and the MAF from the corresponding weight

file exceeds a user-specified MAF difference threshold. The effect sizes from each weight file

are used to initialize K separate instances of the WeightEstimator class. These K

WeightEstimator objects are used as base estimators and fit on genotype and expression data

from the validation data.

Only SR-TWAS models trained from $K = 2, 4, 6$ base models are presented in this paper. The

code was designed to accept any $K \geq 2$, and while the stacked regression script has been

primarily tested using $K = 2, 4, 6$ base models, preliminary testing with dummy weight files

confirms it can train stacked regression models from $K > 6$ base models.

ROS/MAP Reference Panel

The Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP) are two

ongoing longitudinal, epidemiologic clinical-pathologic cohort studies of aging and Alzheimer's

disease collectively referred to as ROS/MAP[10]. ROS enrolls Catholic nuns, priests, and brothers

from religious groups across the United States, primarily from communal living settings[10]. While

the similar adult lifestyle of participants allows for more control of potential confounders such as

education and socioeconomic status, it simultaneously limits the ability to study such variables[10].

MAP was designed to complement and extend studies like ROS by including subjects from a

wider range of life experiences, socioeconomic status, and educational attainment and recruits

participants primarily from retirement communities in the Chicago area, but also subsidized

housing, retirement homes, and through organizations serving minorities and low-income

elderly[10]. All participants in both studies are without known dementia and agree to annual

clinical evaluations and brain donation upon death[10]. Similarity in study design and data

collection procedures allows the ROS and MAP datasets to be merged for use in joint

analyses[10,67].

Quality-controlled ROS/MAP WGS data for European subjects[67] were used for both the real data

application and simulation studies. Transcriptomic data of ROS/MAP samples of brain PFC were

profiled by RNA-sequencing (RNA-seq). Gene expression data of Transcripts Per Million (TPM)

per sample were provided by Rush Alzheimer's Disease Center. Genes with > 0.1 TPM in ≥ 10

samples were considered. Raw gene expression data (TPM) were then log2 transformed and

adjusted for age at death, sex, postmortem interval, study (ROS or MAP), batch effects, RNA

integrity number scores, cell type proportions (with respect to oligodendrocytes, astrocytes,

microglia, neurons), top five genotype principal components, and top probabilistic estimation of

expression residuals (PEER) factors[68] by linear regression models. SNPs with minor allele

frequency (MAF) $> 1\%$, Hardy-Weinberg p-value $> 10^{-5}$ were analyzed. For each gene, cis-

SNPs within the 1MB of the flanking 5' and 3' ends were used in the imputation models as

predictors.

GTEx V8 Reference Panel

The Genotype-Tissue Expression (GTEx) project V8 profiles both whole genome sequencing

(WGS) genotype data and RNA-seq transcriptomic data for Brain PFC tissue type of n=157

donors[9]. Gene expression data of Transcripts Per Million (TPM) per sample per tissue were

downloaded from the GTEx portal. Genes with > 0.1 TPM in ≥ 10 samples were considered.

Raw gene expression data (TPM) were then log2 transformed and adjusted for age, body mass

index (BMI), top five genotype principal components, and top probabilistic estimation of

expression residuals (PEER) factors[68]. SNPs with minor allele frequency (MAF) > 1%, Hardy-

Weinberg p-value $> 10^{-5}$ were analyzed. For each gene, cis- SNPs within the 1MB of the

flanking 5' and 3' ends were used in the imputation models as predictors.

Simulation Study Design

We conducted in depth simulation studies under various scenarios to assess the performance of

SR-TWAS, Naïve method, and base models by PrediXcan and TIGAR. We used the real

genotype data of gene *ABCA7* from ROS/MAP and GTEx V8 to simulate gene expression and

phenotypes. We considered three different settings: (i) Samples from ROS/MAP and GTEx

cohorts have the same set of true causal SNPs (i.e., the same genetic architecture). The

expression heritability was the same for both ROS/MAP and GTEx V8 cohorts. (ii) Samples

from ROS/MAP and GTEx cohorts have the same set of true causal SNPs (i.e., the same genetic

architecture). The expression heritability for GTEx V8 cohort is only half of the one for

ROS/MAP. (iii) Samples from the ROS/MAP cohort were simulated with the same causal SNPs

(i.e., eQTL), while samples from the GTEx V8 cohort were simulated with true causal SNPs that

were 50% overlapped with the ones for ROS/MAP. The expression heritability was the same for

both ROS/MAP and GTEx V8 cohorts.

Under each setting, we considered multiple scenarios with varying proportions of causal SNPs

($p_{causal} = (0.001, 0.01, 0.05, 0.1)$) and gene expression heritability (i.e., the proportion of gene

expression variation due to genetics, $h_e^2 = (0.1, 0.2, 0.5)$). We randomly selected n=465 training

samples with WGS genotype data from ROS/MAP and GTEx V8, respectively. We randomly

selected n=400 and n=800 samples with WGS genotype data from ROS/MAP as our validation

and test cohorts, respectively. We considered a series of h_p^2 values, the proportion of phenotype

variance due to simulated gene expression, in the range of $(0.05, 0.875)$.

For each scenario, gene expression $\mathbf{E}_i$ for the ith simulation iteration is generated using the

following formula

$$\mathbf{E}_i = \gamma_i \mathbf{G}^* \boldsymbol{\beta}_i + \boldsymbol{\varepsilon}_i, \ \gamma_i = \sqrt{\frac{h_e^2}{\mathrm{Var}(\mathbf{G}^* \boldsymbol{\beta}_{\bullet i})}}, \ \boldsymbol{\varepsilon}_i \sim \mathrm{N}\left(0, \sqrt{1 - h_e^2}\right),$$

638   where $\mathbf{G}^*$ denotes the genotype matrix of N_{causal} randomly chosen true causal SNPs for all

639   samples, effect size vector $\boldsymbol{\beta}_i$ was generated from $N(0, I)$, and γ_i is a scale factor chosen to

640   ensure the targeted h_e^2 value. The phenotype vector $\mathbf{Y}_i$ for the ith simulation iteration was

641   generated using the following formula

$$\mathbf{Y}_i = \varphi_i \mathbf{E}_i + \boldsymbol{\varepsilon}_i, \ \varphi_i = \sqrt{\frac{h_p^2}{\mathrm{Var}(\mathbf{E}_i)}}, \ \boldsymbol{\varepsilon}_i \sim \mathrm{N}\left(0, \sqrt{1 - h_p^2}\right)$$

where $\mathbf{E}_i$ is the simulated gene expression, and φ_i is a scale factor to ensure the targeted h_p^2

value.

Two base models per gene were trained by PrediXcan with the GTEx training samples (n=465),

and by TIGAR with the ROS/MAP training samples (n=465). SR-TWAS and Naïve models

were then obtained by using these trained base models. Validation data ($n = 400$) were used to

train SR-TWAS models and filter out gene expression imputation models with 5-fold cross-

validation $R^2 < 0.5\%$ in the validation cohort for both SR-TWAS and Naïve models. Test data

(n=800) were used for assessing GReX prediction performance and TWAS power. Each causal

simulation scenario was repeated for 1,000 times. We compared the performance by SR-TWAS,

Naïve method, and these two base models with respect to prediction imputation R^2 in the test

data and the power of TWASs.

The predicted $\widehat{\text{GReX}}_i$ by each trained gene expression imputation model was used to calculate

expression prediction R^2, which is equivalent to the regression R^2 between profiled and

predicted gene expression, given by

$$R^2_{E_i} = \text{Cor}\left(\mathbf{E}_i, \widehat{\text{GReX}}_i\right)^2.$$

The power will be given by the proportion of simulation iterations that have TWAS p-value

$< 2.5 \times 10^6$ out of a total of 1,000 simulation iterations.

Data availability

All ROS/MAP data analyzed in this study are de-identified and available to any qualified

investigator with application through the Rush Alzheimer's Disease Center Research Resource

Sharing Hub, https://www.radc.rush.edu, which has descriptions of the studies and available

data. GTEx V8 data are available from dbGaP with accession phs000424.v8.p2. TIGAR_GTEx

base models trained from GTEx V8 are available at Synapse

https://www.synapse.org/TIGAR_V2_Resource_GTExV8. PrediXcan_GTEx base models

trained from GTEx V8 are available from https://predictdb.org/. GWAS summary data of AD are

available from https://ctg.cncr.nl/software/summary_statistics, and GWAS summary data of PD

are available from https://bit.ly/2ofzGrk. TIGAR_ROSMAP and PrediXcan_ROSMAP base

models trained from ROS/MAP, trained SR-TWAS and Naïve models of brain PFC tissue type

in this study, and all TWAS summary statistics will be made available at SYNAPSE when the

manuscript is accepted for publication.

Code availability

The SR-TWAS tool, including the Naïve method as an option, is publicly available on GitHub,

https://github.com/yanglab-emory/SR-TWAS.

References

1. Feng, H. *et al.* Transcriptome☐wide association study of breast cancer risk by estrogen☐receptor status. *Genet. Epidemiol.* **44**, 442–468 (2020).

2. Kar, S. *et al.* Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies new candidate susceptibility genes for breast and ovarian cancer. *bioRxiv* (2020) doi:10.1101/2020.04.23.043653.

3. Strunz, T., Lauwen, S., Kiel, C., Hollander, A. den & Weber, B. H. F. A transcriptome-wide association study based on 27 tissues identifies 106 genes potentially relevant for disease pathology in age-related macular degeneration. *Scientific Reports* **10**, 1584 (2020).

4. Wu, C. *et al.* Transcriptome-wide association study identifies susceptibility genes for rheumatoid arthritis. *Arthritis Res Ther* **23**, (2021).

5. Wainberg, M. *et al.* Opportunities and challenges for transcriptome-wide association studies. *Nat Genet* **51**, 592–599 (2019).

6. Nagpal, S. *et al.* TIGAR: An Improved Bayesian Tool for Transcriptomic Data Imputation Enhances Gene Mapping of Complex Traits. *The American Journal of Human Genetics* **105**, 258–266 (2019).

7. Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. *Nat Commun* **9**, 1–20 (2018).

8. Parrish, R. L., Gibson, G. C., Epstein, M. P. & Yang, J. TIGAR-V2: Efficient TWAS tool with nonparametric Bayesian eQTL weights of 49 tissue types from GTEx V8. *Human Genetics and Genomics Advances* **3**, 100068 (2022).

9. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science* **369**, 1318–1330 (2020).

700   10.   Bennett, D. A. *et al.* Religious Orders Study and Rush Memory and Aging Project. *J*
701   *Alzheimers Dis* **64**, S161–S189 (2018).

702   11.   Hu, Y. *et al.* A statistical framework for cross-tissue transcriptome-wide association
703   analysis. *Nat Genet* **51**, 568–576 (2019).

704   12.   Liu, A. E. & Kang, H. M. Meta-imputation of transcriptome from genotypes across multiple
705   datasets by leveraging publicly available summary-level data. *PLOS Genetics* **18**, e1009571
706   (2022).

707   13.   Wolpert, D. H. Stacked generalization. *Neural Networks* **5**, 241–259 (1992).

708   14.   Breiman, L. Stacked regressions. *Mach Learn* **24**, 49–64 (1996).

709   15.   Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association
710   studies. *Nature Genetics* **48**, 245–252 (2016).

711   16.   Wightman, D. P. *et al.* A genome-wide association study with 1,126,563 individuals
712   identifies new risk loci for Alzheimer's disease. *Nat Genet* **53**, 1276–1282 (2021).

713   17.   Mancuso, N. *et al.* Integrating Gene Expression with Summary Association Statistics to
714   Identify Genes Associated with 30 Complex Traits. *The American Journal of Human*
715   *Genetics* **100**, 473–487 (2017).

716   18.   Marioni, R. E. *et al.* GWAS on family history of Alzheimer's disease. *Transl Psychiatry* **8**,
717   99 (2018).

718   19.   Jansen, I. E. *et al.* Genome-wide meta-analysis identifies new loci and functional pathways
719   influencing Alzheimer's disease risk. *Nat Genet* **51**, 404–413 (2019).

720   20.   Nazarian, A., Yashin, A. I. & Kulminski, A. M. Genome-wide analysis of genetic
721   predisposition to Alzheimer's disease and related sex disparities. *Alz Res Therapy* **11**, 1–21
722   (2019).

21. Gockley, J. *et al.* Multi-tissue neocortical transcriptome-wide association study implicates 8

genes across 6 genomic loci in Alzheimer's disease. *Genome Medicine* **13**, 76 (2021).

22. Jing, Q. *et al.* A Comprehensive Analysis Identified Hub Genes and Associated Drugs in

Alzheimer's Disease. *BioMed Research International* **2021**, e8893553 (2021).

23. Kunkle, B. W. *et al.* Genetic meta-analysis of diagnosed Alzheimer's disease identifies new

risk loci and implicates Aβ, tau, immunity and lipid processing. *Nat Genet* **51**, 414–430

(2019).

24. Schwartzentruber, J. *et al.* Genome-wide meta-analysis, fine-mapping, and integrative

prioritization implicate new Alzheimer's disease risk genes. *Nat Genet* **53**, 392–402 (2021).

25. Lambert, J.-C. *et al.* Genome-wide association study identifies variants at CLU and CR1

associated with Alzheimer's disease. *Nat Genet* **41**, 1094–1099 (2009).

26. Jonsson, T. *et al.* Variant of TREM2 Associated with the Risk of Alzheimer's Disease. *N*

Engl J Med **368**, 107–116 (2013).

27. Tang, H. & Harte, M. Investigating Markers of the NLRP3 Inflammasome Pathway in

Alzheimer's Disease: A Human Post-Mortem Study. *Genes (Basel)* **12**, 1753 (2021).

28. Shigemizu, D. *et al.* Ethnic and trans-ethnic genome-wide association studies identify new

loci influencing Japanese Alzheimer's disease risk. *Transl Psychiatry* **11**, 1–10 (2021).

29. Deming, Y. *et al.* The MS4A gene cluster is a key modulator of soluble TREM2 and

Alzheimer's disease risk. *Science Translational Medicine* **11**, eaau2291 (2019).

30. Jimenez☐Marin, A. *et al.* Transcriptional signatures of synaptic vesicle genes define

myotonic dystrophy type I neurodegeneration. *Neuropathol Appl Neurobiol* **47**, 1092–1108

(2021).

31. Burdelski, C. *et al.* Family with sequence similarity 13C (FAM13C) overexpression is an

independent prognostic marker in prostate cancer. *Oncotarget* **8**, 31494–31508 (2017).

32. Lin, H.-C. *et al.* Alzheimer's disease is associated with prostate cancer: a population-based

study. *Oncotarget* **9**, 7616–7622 (2018).

33. Pereira, J. B. *et al.* Plasma GFAP is an early marker of amyloid-β but not tau pathology in

Alzheimer's disease. *Brain* **144**, 3505–3516 (2021).

34. Akram, A. *et al.* Stereologic estimates of total spinophilin-immunoreactive spine number in

area 9 and the CA1 field: Relationship with the progression of Alzheimer's disease.

Neurobiology of Aging **29**, 1296–1307 (2008).

35. Mi, Z. *et al.* Loss of precuneus dendritic spines immunopositive for spinophilin is related to

cognitive impairment in early Alzheimer's disease. *Neurobiology of Aging* **55**, 159–166

(2017).

36. Wu, M. *et al.* Hippocampal overexpression of TREM2 ameliorates high fat diet induced

cognitive impairment and modulates phenotypic polarization of the microglia. *Genes &*

Diseases **9**, 401–414 (2022).

37. Song, F. *et al.* Regulation and biological role of the peptide/histidine transporter SLC15A3

in Toll-like receptor-mediated inflammatory responses in macrophage. *Cell Death Dis* **9**, 1–

15 (2018).

38. Nalls, M. A. *et al.* Identification of novel risk loci, causal insights, and heritable risk for

Parkinson's disease: a meta-analysis of genome-wide association studies. *The Lancet*

Neurology **18**, 1091–1102 (2019).

39. Yao, S. *et al.* A transcriptome-wide association study identifies susceptibility genes for

Parkinson's disease. *npj Parkinsons Dis.* **7**, 1–8 (2021).

40.   Kia, D. A. *et al.* Identification of Candidate Parkinson Disease Genes by Integrating

769   Genome-Wide Association Study, Expression, and Epigenetic Data Sets. *JAMA Neurology*

770   **78**, 464–472 (2021).

771   41.   Robak, L. A. *et al.* Excessive burden of lysosomal storage disorder gene variants in

772   Parkinson's disease. *Brain* **140**, 3191–3203 (2017).

773   42.   Subrahmanian, N. & LaVoie, M. J. Is there a special relationship between complex I

774   activity and nigral neuronal loss in Parkinson's disease? A critical reappraisal. *Brain*

775   *Research* **1767**, 147434 (2021).

776   43.   Storm, C. S. *et al.* Finding genetically-supported drug targets for Parkinson's disease using

777   Mendelian randomization of the druggable genome. *Nat Commun* **12**, 7342 (2021).

778   44.   Prokop, J. W. *et al.* Characterization of Coding/Noncoding Variants for SHROOM3 in

779   Patients with CKD. *J Am Soc Nephrol* **29**, 1525–1535 (2018).

780   45.   Meléndez-Flores, J. D. & Estrada-Bellmann, I. Linking chronic kidney disease and

781   Parkinson's disease: a literature review. *Metab Brain Dis* **36**, 1–12 (2021).

782   46.   Sikora, J. & Ouagazzal, A.-M. Synaptic Zinc: An Emerging Player in Parkinson's Disease.

783   *Int J Mol Sci* **22**, 4724 (2021).

784   47.   Guerreiro, S., Privat, A.-L., Bressac, L. & Toulorge, D. CD38 in Neurodegeneration and

785   Neuroinflammation. *Cells* **9**, 471 (2020).

786   48.   Moloney, E. B., Moskites, A., Ferrari, E. J., Isacson, O. & Hallett, P. J. The glycoprotein

787   GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and

788   increases after lysosomal stress. *Neurobiology of Disease* **120**, 1–11 (2018).

789   49.   Purlyte, E. *et al.* Rab29 activation of the Parkinson's disease-associated LRRK2 kinase. *The*

790   *EMBO Journal* **37**, 1–18 (2018).

50. Sagi, O. & Rokach, L. Ensemble learning: A survey. *WIREs Data Mining and Knowledge*

Discovery **8**, e1249 (2018).

51. Mogil, L. S. *et al.* Genetic architecture of gene expression traits across diverse populations.

PLOS Genetics **14**, e1007586 (2018).

52. Luningham, J. M. *et al.* Bayesian Genome-wide TWAS Method to Leverage both cis- and

trans-eQTL Information through Summary Statistics. *The American Journal of Human*

Genetics **107**, 714–726 (2020).

53. Yang, C. *et al.* CoMM: a collaborative mixed model to dissecting genetic contributions to

complex traits by leveraging regulatory information. *Bioinformatics* **35**, 1644–1652 (2019).

54. Yuan, Z. *et al.* Testing and controlling for horizontal pleiotropy with probabilistic

Mendelian randomization in transcriptome-wide association studies. *Nature*

Communications **11**, 3861 (2020).

55. Tang, S. *et al.* Novel Variance-Component TWAS method for studying complex human

diseases with applications to Alzheimer's dementia. *PLOS Genetics* **17**, e1009482 (2021).

56. Rao, J. N. K. & Subrahmaniam, K. Combining Independent Estimators and Estimation in

Linear Regression with Unequal Variances. *Biometrics* **27**, 971–990 (1971).

57. Efron, B. & Morris, C. Combining Possibly Related Estimation Problems. *Journal of the*

Royal Statistical Society **35**, 379–421 (1973).

58. Wu, L. *et al.* A transcriptome-wide association study of 229,000 women identifies new

candidate susceptibility genes for breast cancer. *Nat Genet* **50**, 968–978 (2018).

59. Bhattacharya, A., Li, Y. & Love, M. I. MOSTWAS: Multi-Omic Strategies for

Transcriptome-Wide Association Studies. *PLoS Genet* **17**, e1009398 (2021).

60.   Li, H. Tabix: fast retrieval of sequence features from generic TAB-delimited files.

Bioinformatics **27**, 718–719 (2011).

61.   McKinney, W. Data Structures for Statistical Computing in Python. in *Proceedings of the*

9th Python in Science Conference (SciPy 2010) 56–61 (2010). doi:10.25080/Majora-

92bf1922-00a.

62.   Harris, C. R. *et al.* Array programming with NumPy. *Nature* **585**, 357–362 (2020).

63.   Virtanen, P. *et al.* SciPy 1.0: fundamental algorithms for scientific computing in Python.

Nature Methods **17**, 261–272 (2020).

64.   Seabold, S. & Perktold, J. Statsmodels: Econometric and Statistical Modeling with Python.

in *Proceedings of the 9th Python in Science Conference (SciPy 2010)* 92–96 (2010).

doi:10.25080/Majora-92bf1922-011.

65.   Pedregosa, F. *et al.* Scikit-learn: Machine learning in python. *Journal of Machine Learning*

Research **12**, 2825–2830 (2011).

66.   Buitinck, L. *et al.* API design for machine learning software: experiences from the scikit-

learn project. in *Proceedings of the European Conference on Machine Learning and*

Principles and Practices of Knowledge Discovery in Databases (ECMPKDD'13) 108--122

(2013).

67.   De Jager, P. L. *et al.* A multi-omic atlas of the human frontal cortex for aging and

Alzheimer's disease research. *Sci Data* **5**, (2018).

68.   Stegle, O., Parts, L., Piipari, M., Winn, J. & Durbin, R. Using probabilistic estimation of

expression residuals (PEER) to obtain increased power and interpretability of gene

expression analyses. *Nat Protoc* **7**, 500–507 (2012).

835